Over the last two decades, the principle of PBM has been formulated, recognising that retaining a patient’s own blood within their circulatory system is the most advantageous for their health. Despite advancements in medical science, the issue persists: there is an excessive dependence on blood transfusions despite their known risks. This overreliance leads to avoidable adverse outcomes, depletion of limited blood resources, and inefficient use of healthcare funds. CSL Vifor views a solution to this in PBM: an evidence‑based approach to improve outcomes by preserving patient’s own blood. Due to the well-established benefits of PBM, there is positive momentum behind its implementation, supported by the World Health Organization, EU commission and national guidelines. The stage is set therefore for broadscale PBM adoption. CSL Vifor is uniquely positioned in PBM to translate evidence-based medicine into evidence-based practice. The portfolio addresses ID (iron deficiency)/IDA (iron deficiency anemia) management pre and post operation to reduce blood transfusions and improve surgical patient outcomes. The CSL Behring portfolio addresses minimising blood loss through optimising hemostasis and attacking coagulation deficiencies, therefore reducing surgical blood use. Read more at investors.csl.com By bringing together this expertise and these products from CSL Vifor and CSL Behring, CSL is positioned to become the foremost and reliable partner in “blood health”, significantly enhancing patient care. Over the longer term, CSL is aiming to strengthen our renal disease position to offer medicines to patients at all stages of chronic kidney disease (CKD). Our ambition is to further expand the portfolio from dialysis to prevention of kidney damage, treatment of CKD complications and transplant. The market reveals a significant unmet need. The conditions targeted by CSL Vifor are inadequately served and represent a compelling opportunity for growth. It is estimated that the renal disease market will grow at a steady pace. This growth will be driven by an aging population and increased prevalence of CKD risk factors such as diabetes and heart disease. CSL aims to satisfy this unmet need by further expanding the portfolio from dialysis to prevention of kidney damage, treatment of CKD complications and transplant. CSL’s Businesses and Outlook CSL Vifor’s commercial portfolio addresses significant unmet need in patient journeys in iron deficiency and nephrology. Over the short term, CSL has prepared for challenges, however its growth ambitions are supported by multiple strategic and operational initiatives. These include geographic expansion, new indications, enhanced tender capabilities, investing in real-world evidence, life cycle management and driving additional value for the CSL Vifor and CSL Behring offerings from Patient Blood Management (PBM). CSL Vifor is well positioned for the evolving iron market. The clear ambition is to retain a leadership position in iron despite the competitive generic environment, including the loss of exclusivity (LoE) of CSL Vifor’s flagship product FERINJECT® in some markets. To date, global iron volumes have remained robust in Europe. This marks an important moment for the business, but it is well prepared and strategically positioned to meet the challenge. The fact remains that the intravenous (IV) iron market is largely untapped, with 85% of eligible patients not receiving IV iron treatment. The market is therefore expected to continue to grow in volume, in line with historical trends, presenting opportunities for CSL Vifor to drive long‑term, sustainable growth. 18 Limited Annual Report 2023/24
RkJQdWJsaXNoZXIy MjE2NDg3